SUPN vs TXG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.
TXG exhibits a stark divergence between its strong balance sheet liquidity and its poor operational health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a very low Debt/Equity ratio (0.11) and a robust Current Ratio (4.46), revenue growth has stagnated at 0.60% YoY. The stock is currently trading at a significant premium with a Forward P/E of 114.85, despite negative profit margins. Recent price recovery is strong, but insider selling and bearish technical trends suggest caution.
Compare Another Pair
Related Comparisons
SUPN vs TXG: Head-to-Head Comparison
This page compares Supernus Pharmaceuticals, Inc. (SUPN) and 10x Genomics, Inc. (TXG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.